News
-
-
PRESS RELEASE
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announced a private placement of convertible promissory notes to selected investors for working capital. H.C. Wainwright & Co. is the placement agent -
-
-
-
PRESS RELEASE
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Jaguar Health announces voting results of Special Meeting of Stockholders and expect first results in Q2 2025 for crofelemer trials in rare diseases. FDA meeting anticipated for Phase 3 OnTarget trial in breast cancer patients -
-
PRESS RELEASE
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
Jaguar Health, Inc. announces results of crofelemer trials for rare diseases and adoption of Rights Plan to deter open-market accumulation. FDA meeting expected in Q2 2025 for breast cancer study results -
-
PRESS RELEASE
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health, Inc. announces initiation of clinical trial for crofelemer in rare diseases SBS-IF and MVID. First proof-of-concept results expected in H1 2025
